Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on
cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild
Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory
complaint patients cognitively normal (CNE). The first phase includes four weeks treatment
with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18
FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU)
period with EGb761® treatment in MC and CNE patients.